



## UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37<sup>th</sup> Annual Healthcare Conference to take place on December 2-4, 2025.

### Piper Sandler 37th Annual Healthcare Conference

Date / Time: December 2, 2025, at 1:00 PM ET  
Format: Fireside Chat  
Location: New York, NY  
Webcast Link: [here](#)

Webcasts from the conferences will also be available on UroGen's Investor Relations [website](#). A replay will be available on the site for approximately 90 days.

### About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel<sup>®</sup> reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit [www.urogen.com](http://www.urogen.com) to learn more or follow us on X, @UroGenPharma.

### INVESTORS:

Vincent Perrone  
Senior Director, Investor Relations  
[vincent.perrone@urogen.com](mailto:vincent.perrone@urogen.com)  
609-460-3588 ext. 1093

### MEDIA:

Cindy Romano  
Director, Corporate Communications  
[cindy.romano@urogen.com](mailto:cindy.romano@urogen.com)  
609-460-3583 ext. 1083



Source: UroGen Pharma Ltd.